Cell Therapy Company Rexgenero Utilizes HemaCare’s Bone Marrow Products for Development of their Critical Limb Ischemia Therapeutic
Cell Therapy Company Rexgenero Utilizes HemaCare’s Bone Marrow Products for Development of their Critical Limb Ischemia Therapeutic
2 PagesCustomer Case Study | Rexgenero | Bone Marrow Aspirate Cell Therapy Company Rexgenero Utilizes HemaCare’s Bone Marrow Products for Development of their Critical Limb Ischemia Therapeutic Introduction Rexgenero, a regenerative medicine company based in Seville, Spain, is developing a number of cell-based therapeutics for the treatment of serious diseases such as peripheral artery disease and critical limb ischemia. These diseases are fairly prevalent among the older population, affecting up to 10% of people over the age of 70. [1] The company uses three different cellular technologies, each aimed at regenerating diseased tissues and thereby treating the underlying cause of the disease, rather than simply slowing disease progression or treating symptoms. Rexgenero’s lead candida
